ReNerve Lands Malaysian Distribution Deal to Push NervAlign Into 33M-Person Market

ReNerve secures UG Medical as Malaysian distribution partner for NervAlign

ReNerve Limited (ASX: RNV) has executed a distribution agreement with UG Medical Services Sdn Bhd, appointing the Kuala Lumpur-based company as its commercialisation partner for NervAlign products in Malaysia. The NervAlign Nerve Cuff received regulatory clearance from Malaysia’s Medical Device Authority (MDA) earlier in 2026, providing a live pathway to market in a country of approximately 33 million people. The agreement carries an open-ended term on customary commercial terms for medical device distribution arrangements, with no financial terms disclosed.

Malaysia represents a meaningful step in ReNerve’s broader Asia-Pacific commercialisation strategy, with the company also targeting a NervAlign Nerve Conduit launch in the country later in 2026.

Dr Julian Chick, CEO & Managing Director of ReNerve

“This agreement with UG Medical represents a compelling opportunity to establish NervAlign in the Malaysian market, which is one of Southeast Asia’s most progressive and well-developed healthcare systems. UG Medical’s relationships and in-market expertise make them an outstanding partner for ReNerve as we continue to build our commercial presence across the Asia-Pacific region.”

What this deal means for NervAlign’s commercial footprint

UG Medical’s role and responsibilities

UG Medical is a Kuala Lumpur-based medical device distributor with an established national presence across Malaysian hospitals and healthcare facilities, and a track record of introducing innovative medical devices to the market and supporting clinical adoption through specialist engagement.

Under the agreement, UG Medical will be responsible for:

• Importation and warehousing of NervAlign products
• Regulatory management in-country
• Marketing, sales, and distribution across Malaysia
• Clinical adoption support through specialist engagement

ReNerve’s supporting commitments

ReNerve retains responsibility for ongoing clinical and technical support, product training, and regulatory liaison to underpin UG Medical’s commercialisation activities. Importantly, ReNerve’s Asia sales and marketing team has already established relationships with hospitals in the region, meaning the Malaysian entry builds on existing connections rather than starting from scratch.

An immediate commercial activation opportunity is also in place. ReNerve will be a major sponsor of the hand surgery teaching event in Kuala Lumpur in June 2026, providing direct access to the specialist surgical community at a high-profile educational forum.

Understanding Malaysia’s healthcare opportunity

Malaysia stands out as one of Southeast Asia’s more developed and strategically attractive healthcare markets for a specialist surgical device like NervAlign. The country operates a dual healthcare infrastructure, with a well-established public hospital network complemented by a growing private sector, together providing broad reach for medical device commercialisation.

The Malaysian government’s 12th Malaysia Plan includes a firm commitment to ongoing investment in healthcare infrastructure, with particular emphasis on surgical capability and specialist services. For a company targeting surgeons in the peripheral nerve repair space, this policy backdrop means more trained specialists and better-equipped facilities over time, expanding the addressable market for procedures where NervAlign is indicated.

Peripheral nerve injuries represent a significant and underserved clinical need globally. The global nerve repair market was valued at US$1.6 billion in 2024 and is projected to reach US$6.2 billion by 2031, reflecting the scale of unmet demand. Malaysia’s growing surgical sophistication and government-backed infrastructure investment position the country as a market where adoption of specialist devices like NervAlign can accelerate alongside systemic healthcare development.

With a population of approximately 33 million, Malaysia’s combination of healthcare investment, dual public-private infrastructure, and expanding specialist workforce presents a meaningful commercial opportunity for ReNerve’s product range.

Building momentum across Asia-Pacific

The UG Medical appointment is part of ReNerve’s deliberate Asia-Pacific commercialisation strategy rather than an isolated transaction. UG Medical is positioned as a distribution channel for multiple products, with the NervAlign Nerve Conduit targeted for Malaysian launch later in 2026, adding pipeline depth to the relationship beyond the Nerve Cuff.

ReNerve’s US commercial performance provides a credible foundation for this expansion. The company achieved $271k in revenue in FY25, representing 53% year-on-year growth, with FY26 year-to-date sales described as showing further significant increases across its portfolio. FDA clearance in the US preceded MDA clearance in Malaysia, and that established commercial track record supports the case for international expansion.

Dr Julian Chick, CEO & Managing Director of ReNerve

“NervAlign addresses a significant and underserved clinical need in peripheral nerve repair and Malaysia’s growing investment in surgical infrastructure and specialist care creates a strong environment for adoption. We look forward to working with the UG Medical team to bring NervAlign to surgeons and patients across Malaysia.”

The table below summarises NervAlign’s current market status across key geographies:

Don’t Miss the Next Healthcare Breakout on the ASX

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers already rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button to start receiving alerts the moment ASX healthcare stocks make their next move.